The malignant tumor is a multi-etiological, systemic and complex disease characterized by
uncontrolled cell proliferation and distant metastasis. Anticancer treatments including …

Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …

Single-cell RNA-sequencing has emerged as a powerful technique for characterizing
cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Biological heterogeneity in diffuse large B cell lymphoma (DLBCL) is partly driven by cell-of-
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …